NASDAQ:VCYT

Veracyte (VCYT) Stock Forecast, Price & News

$22.47

-0.13 (-0.58%)

(As of 09/22/2023 ET)

Compare

Today's Range: $22.21
▼
$22.98
50-Day Range: $22.47
▼
$29.92
52-Week Range: $14.92
▼
$32.40

Volume: 439,060 shs
Average Volume: 482,328 shs
Market Capitalization: $1.63 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.60

Veracyte MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 36.2% Upside
$30.60 Price Target
Short Interest: Healthy
3.49% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.03
Upright™ Environmental Score
News Sentiment: 0.79
Based on 2 Articles This Week
Insider Trading: Selling Shares
$305,000 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.52) to ($0.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

347th out of 963 stocks

Medical Laboratories Industry

8th out of 23 stocks

3.3

Analyst's Opinion

Consensus Rating
Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $30.60, Veracyte has a forecasted upside of 36.2% from its current price of $22.47.
Amount of Analyst Coverage
Veracyte has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.49% of the outstanding shares of Veracyte have been sold short.
Short Interest Ratio / Days to Cover
Veracyte has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Veracyte has recently decreased by 11.81%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Veracyte does not currently pay a dividend.
Dividend Growth
Veracyte does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Veracyte has received a 67.08% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Genomics analysis tools", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Veracyte is -1.03.

2.1

News and Social Media Coverage

News Sentiment
Veracyte has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Veracyte this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $305,000.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of Veracyte is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Veracyte are expected to grow in the coming year, from ($0.52) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veracyte is -56.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veracyte is -56.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veracyte has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Price History

30 days | 90 days | 365 days | Advanced Chart

VCYT Stock News Headlines

September 21, 2023 | finance.yahoo.com

Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

September 15, 2023 | es.investing.com

Veracyte Inc (VCYT)

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 7, 2023 | finance.yahoo.com

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests

September 6, 2023 | finance.yahoo.com

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

September 2, 2023 | msn.com

Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?

August 29, 2023 | businesswire.com

Veracyte to Participate in the Morgan Stanley 21 st Annual Global Healthcare Conference

August 29, 2023 | finance.yahoo.com

Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 24, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

August 17, 2023 | seekingalpha.com

Veracyte: Testing Numbers Stretching Higher But Valuations Uncertain

August 15, 2023 | finance.yahoo.com

Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego

August 10, 2023 | msn.com

Morgan Stanley Maintains Veracyte (VCYT) Underweight Recommendation

August 9, 2023 | msn.com

Needham Maintains Veracyte (VCYT) Buy Recommendation

August 8, 2023 | seekingalpha.com

Veracyte, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 8, 2023 | finance.yahoo.com

Veracyte Announces Second Quarter 2023 Financial Results

July 25, 2023 | benzinga.com

Director At This Health Care Company Sells $118K of Stock

July 19, 2023 | finance.yahoo.com

Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023

June 20, 2023 | finance.yahoo.com

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

June 12, 2023 | benzinga.com

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

May 30, 2023 | finance.yahoo.com

Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors

May 25, 2023 | benzinga.com

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte's Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

May 24, 2023 | finance.yahoo.com

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

May 22, 2023 | finance.yahoo.com

Here's Why This Little-Known Growth Stock Is a Buy

May 17, 2023 | msn.com

Looking Into Veracyte's Return On Capital Employed

May 16, 2023 | seekingalpha.com

Veracyte: Investing In The Future Of Genomic Diagnostics

May 10, 2023 | theglobeandmail.com

A New Groundbreaking Tool to Detect Colon Cancer Earlier

May 10, 2023 | msn.com

Stephens & Co. Reiterates Veracyte (VCYT) Overweight Recommendation

See More Headlines

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings: 8/08/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VCYT
CUSIP: N/A
CIK: 1384101
Web: www.veracyte.com
Phone: (650) 243-6300
Fax: 650-243-6301
Employees: 787
Year Founded: 2006

Price Target and Rating

Average Stock Price Forecast: $30.60
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +36.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,560,000.00
Net Margins: -8.84%
Pretax Margin: -8.73%
Return on Equity: -2.71%
Return on Assets: -2.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.46
Quick Ratio: 4.26

Sales & Book Value

Annual Sales: $296.54 million
Price / Sales: 5.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.98 per share
Price / Book: 1.50

Miscellaneous

Outstanding Shares: 72,750,000
Free Float: 70,859,000
Market Cap: $1.63 billion
Optionable: Optionable
Beta: 1.32

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Marc A. Stapley (Age 53)
CEO & Director
Comp: $1.25M

Ms. Rebecca Chambers (Age 45)
Exec. VP & CFO
Comp: $772.41k

Ms. Annie McGuire (Age 42)
Exec. VP, Gen. Counsel & Chief People Officer
Comp: $633.65k

Mr. Jonathan Wygant (Age 52)
VP & Chief Accounting Officer

Mr. Steven French
Sr. VP & Chief Information Officer

Ms. Tracy Morris
VP of Global Corp. Communications

Mr. Robert Brainin (Age 51)
Exec. VP & Chief Bus. Officer

Dr. Fabienne Hermitte Ph.D.
Sr. VP of Global Quality & Regulatory Affairs

Dr. John Leite Ph.D.
Chief Commercial Officer for CLIA Bus.

Ms. Corinne Danan
Sr. VP and GM of Biopharma & IVD Services

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings or view top-rated stocks.
What is Veracyte's stock price forecast for 2023?: 6 brokers have issued 1-year price targets for Veracyte's stock. Their VCYT share price forecasts range from $23.00 to $35.00. On average, they predict the company's stock price to reach $30.60 in the next year. This suggests a possible upside of 36.2% from the stock's current price.
View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts.
How have VCYT shares performed in 2023?: Veracyte's stock was trading at $23.73 on January 1st, 2023. Since then, VCYT stock has decreased by 5.3% and is now trading at $22.47.
View the best growth stocks for 2023 here.
When is Veracyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our VCYT earnings forecast.
How were Veracyte's earnings last quarter?: Veracyte, Inc. (NASDAQ:VCYT) announced its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.04. The biotechnology company earned $90.32 million during the quarter, compared to analysts' expectations of $83.05 million. Veracyte had a negative trailing twelve-month return on equity of 2.71% and a negative net margin of 8.84%. Veracyte's revenue for the quarter was up 24.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.13) earnings per share.
What ETFs hold Veracyte's stock?: ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW).
What guidance has Veracyte issued on next quarter's earnings?: Veracyte issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$350.00 million, compared to the consensus revenue estimate of $335.77 million.
What other stocks do shareholders of Veracyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?: Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
Who are Veracyte's major shareholders?: Veracyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (48.69%), ARK Investment Management LLC (10.81%), BlackRock Inc. (9.50%), State Street Corp (4.97%), Artisan Partners Limited Partnership (4.89%) and Sumitomo Mitsui Trust Holdings Inc. (4.49%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, John Walter Hanna Jr, Karin Eastham, Kevin K Gordon, Marc Stapley, Mark Ho and Muna Bhanji.
View institutional ownership trends.
How do I buy shares of Veracyte?: Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Veracyte's stock price today?: One share of VCYT stock can currently be purchased for approximately $22.47.
How much money does Veracyte make?: Veracyte (NASDAQ:VCYT) has a market capitalization of $1.63 billion and generates $328.63 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.
How many employees does Veracyte have?: The company employs 787 workers across the globe.
Does Veracyte have any subsidiaries?: The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
How can I contact Veracyte?: Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial